P. Juni

Discipline

Gestion et management (1) Economies et finances (1)

Type de document

Articles (12)

Co-auteur

Date

Source

Mot-clé

Patients (11) Patients (11) Death (8) Death (8) mort (8) Treatment (7) Ci (Chinese poetry) (7) Human beings (7) risque (6) Methods (6) Risk (6) Myocardial infarction (6) Methods (6) cohorte (6) procès (5) Syndromes (5) danger (4) maladie (4) taux (4) Rates (4) Confidence (4) Rates (4) maladie (4) étable (3) sécurité (3) polymère (3) association (3) âge (3) Control (3) Year (3)

Documents écrit par P. Juni (12) | parle de P. Juni (0)

Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
J.F. Iglesias et al.
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
T. Pilgrim et al. (22 mars 2021)
Global Fractional Flow Reserve Value Predicts 5-Year Outcomes in Patients With Coronary Atherosclerosis But Without Ischemia.
S. Fournier et al. (15 déc. 2020)
The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial.
R. Wang et al.
Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.
F.M. Zimmermann et al. (7 janv. 2019)
Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention.
D. Carballo et al. (2019)
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.
R. Laaksonen et al. (1 juil. 2016)
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
R. Zbinden et al. (2016)
Health utility indexes in patients with acute coronary syndromes.
B. Gencer et al. (2016)
Subclinical thyroid dysfunction and fracture risk: a meta-analysis.
M.R. Blum et al. (2015)
Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.
D. Nanchen et al. (2015)
Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications.
R. Auer et al. (2014)